Indinavir (indinavir sulphate) – happy family pharmacy
HIV Protease Inhibitor for Antiretroviral Therapy – Buy Over The Counter
What is indinavir?
Indinavir is a potent antiretroviral medication containing Indinavir Sulphate as its active pharmaceutical ingredient. Indinavir belongs to the class of drugs known as HIV protease inhibitors, which represent a major milestone in the evolution of antiretroviral therapy for the treatment of human immunodeficiency virus infection. Indinavir was among the first protease inhibitors to be approved for clinical use in the mid-1990s, and its introduction, along with other protease inhibitors and the concept of highly active antiretroviral therapy combining multiple drug classes, transformed HIV infection from a nearly universally fatal disease into a manageable chronic condition for patients with access to treatment. The medication works by inhibiting the HIV-1 protease enzyme, an aspartic protease that is essential for the viral life cycle. Without functional protease, newly produced viral particles are unable to cleave the gag and gag-pol polyproteins into their mature, functional forms, resulting in the production of non-infectious, immature viral particles that are incapable of infecting new cells. Indinavir is used exclusively as part of combination antiretroviral therapy, never as monotherapy, due to the rapid emergence of drug resistance when a single agent is used. The medication is available as oral capsules in strengths of two hundred milligrams and four hundred milligrams, and the standard dosing regimen involves taking eight hundred milligrams every eight hours, which requires meticulous adherence to the scheduled dosing times for optimal viral suppression. At Happy Family Pharmacy, we offer Indinavir over the counter, providing patients with another option for accessing this essential component of HIV treatment regimens.
The mechanism of action of indinavir against hiv
The antiretroviral activity of Indinavir is grounded in its precise inhibition of the HIV-1 protease enzyme, which plays an indispensable role in the maturation of newly formed viral particles. The life cycle of HIV within a human host cell begins with the attachment of the virus to the CD4 receptor and a co-receptor on the surface of a susceptible cell, followed by fusion of the viral envelope with the cell membrane and entry of the viral core into the cytoplasm. The viral RNA genome is then reverse transcribed into double-stranded DNA by the viral reverse transcriptase enzyme. This newly synthesized viral DNA is transported into the nucleus and integrated into the host cell’s chromosomal DNA through the action of the viral integrase enzyme, establishing a permanent proviral reservoir that persists for the life of the cell. When the integrated provirus is transcriptionally active, the host cell’s machinery transcribes viral genes into messenger RNA, which is translated by ribosomes into long polyprotein chains known as gag and gag-pol. These polyproteins must be cleaved at specific sites by the HIV protease enzyme to release the individual functional proteins required for the assembly of a mature, infectious virion. Among these cleaved products are the structural proteins that form the viral capsid, matrix, and nucleocapsid, and the enzymes reverse transcriptase, integrase, and protease itself. Indinavir is a peptidomimetic inhibitor that was designed through structure-based drug design to fit precisely into the active site of the HIV-1 protease, which is a symmetric homodimer with a catalytic aspartic acid residue at the center of the substrate-binding cleft. By binding tightly to this active site, Indinavir prevents the protease from accessing and cleaving its natural polyprotein substrates. The resulting viral particles that bud from the cell surface contain unprocessed gag and gag-pol polyproteins and are structurally immature, with an aberrant morphology characterized by an incomplete or malformed capsid core. These immature particles are non-infectious and cannot propagate the infection to new cells. The potency of Indinavir and other protease inhibitors is reflected in the deep reductions in plasma viral load that are observed when these agents are added to an antiretroviral regimen in protease inhibitor-naive patients. In the early clinical trials of Indinavir, the addition of the drug to a dual nucleoside reverse transcriptase inhibitor backbone resulted in reductions of plasma HIV RNA by more than two logarithms, often to levels below the limit of detection of the assays available at the time. This suppression of viral replication allows for immune recovery, as manifested by increases in CD4-positive T-lymphocyte counts, which are the primary targets of HIV and whose progressive depletion is the feature of HIV disease progression. The recovery of CD4 cell counts restores the ability of the immune system to defend against opportunistic pathogens, dramatically reducing the incidence of opportunistic infections, malignancies, and death. A key limitation of Indinavir and other protease inhibitors is the relatively low genetic barrier to resistance. Single amino acid substitutions in the protease gene can confer significant resistance to the drug, and the accumulation of multiple mutations over time in patients with incomplete viral suppression leads to high-level resistance and cross-resistance to other protease inhibitors. This characteristic shows the absolute necessity of combining Indinavir with at least two other active antiretroviral agents and of maintaining near-perfect adherence to the prescribed regimen to prevent the emergence of drug-resistant viral populations. The pharmacokinetic properties of Indinavir also influence its antiviral activity and tolerability. The drug has relatively low oral bioavailability that is reduced by food, necessitating administration on an empty stomach for optimal absorption. The plasma half-life of Indinavir is approximately one and a half to two hours, which is shorter than that of most other protease inhibitors and requires an inconvenient eight-hourly dosing schedule to maintain adequate trough concentrations throughout the dosing interval.
The role of indinavir in antiretroviral therapy
Indinavir, as a member of the HIV protease inhibitor class, has played a transformative role in the history of antiretroviral therapy and continues to be used as part of combination regimens for the treatment of HIV-1 infection. The current standard of care for HIV treatment involves the use of combination antiretroviral therapy, which typically consists of two nucleoside or nucleotide reverse transcriptase inhibitors as the backbone, combined with a third active agent from a different drug class, such as a protease inhibitor, an integrase strand transfer inhibitor, or a non-nucleoside reverse transcriptase inhibitor. Indinavir is the third agent in such regimens, providing a mechanism of action that is distinct from and complementary to the reverse transcriptase inhibitors, thereby attacking the viral life cycle at two different points and increasing the barrier to the development of drug resistance. Indinavir may be particularly useful in patients who have developed resistance to other classes of antiretroviral drugs or who have experienced intolerable side effects with alternative agents. The selection of a protease inhibitor for an individual patient depends on multiple factors, including the results of HIV genotypic or phenotypic drug resistance testing, which identifies specific mutations in the viral genome that confer resistance to particular drugs and can guide the selection of agents to which the patient’s virus remains susceptible. Other considerations include the patient’s prior treatment history, the side effect profile of the available agents, the potential for drug-drug interactions with the patient’s other medications, the patient’s preferences regarding dosing frequency and pill burden, and the presence of comorbid conditions such as hepatitis B or C co-infection, cardiovascular disease, or renal impairment. In treatment-naive patients who are initiating antiretroviral therapy for the first time, Indinavir is not typically a first-line choice among protease inhibitors, as newer agents in the class, particularly those that are boosted with low-dose ritonavir or cobicistat to increase drug exposure and prolong the dosing interval, offer advantages in terms of reduced pill burden, less frequent dosing, and improved tolerability. For example, darunavir boosted with ritonavir or cobicistat has a high genetic barrier to resistance, can be dosed once daily, and has a favorable metabolic profile, making it a preferred protease inhibitor in most treatment guidelines. Nevertheless, Indinavir remains a viable option for patients who cannot tolerate or do not have access to the preferred agents, and the clinical experience accumulated with this drug over more than two decades provides a solid evidence base for its efficacy and safety when used appropriately. The combination of Indinavir with two nucleoside reverse transcriptase inhibitors, such as zidovudine plus lamivudine or tenofovir disoproxil fumarate plus emtricitabine, forms a complete antiretroviral regimen that can achieve and maintain virological suppression in a substantial proportion of adherent patients. In patients who have experienced virological failure on other antiretroviral regimens, particularly those that do not include a protease inhibitor, Indinavir may retain activity against the resistant viral population, though genotypic testing should be performed to confirm susceptibility before switching to or adding Indinavir to a salvage regimen. In some treatment-experienced patients with multi-drug resistant virus, Indinavir may be used in combination with other protease inhibitors as part of a double-boosted protease inhibitor strategy, though this approach is less commonly employed now with the availability of newer agents with higher genetic barriers to resistance. The role of Indinavir in pediatric HIV infection is limited, as the safety and efficacy of the drug in children under four years of age have not been established, and alternative agents with more favorable pediatric formulations and dosing schedules are generally preferred. For pregnant women with HIV, the choice of antiretroviral therapy must balance the goal of maximal viral suppression to prevent mother-to-child transmission against the need to minimize fetal exposure to drugs with unknown or adverse effects on fetal development. While Indinavir is classified as FDA Pregnancy Category C, and its use in pregnancy is not routinely recommended, it may be considered if the potential benefit to the mother justifies the potential risk to the fetus and if alternative agents are not suitable.
Dosage and administration of indinavir
The standard adult dose of Indinavir for the treatment of HIV-1 infection is eight hundred milligrams, administered orally every eight hours. This dosing schedule translates to a requirement for medication to be taken three times daily at evenly spaced intervals, which demands a high level of adherence and can present challenges for patients in maintaining privacy about their HIV status, as the need to take medication during the daytime hours may be difficult to conceal. For patients who are co-administered a pharmacokinetic enhancer, specifically low-dose ritonavir at a dose of one hundred to two hundred milligrams twice daily, the dose of Indinavir can be reduced to eight hundred milligrams twice daily, as ritonavir potently inhibits the CYP3A4-mediated metabolism of Indinavir and increases its plasma concentrations and half-life. This ritonavir-boosted regimen reduces the dosing frequency to twice daily, which is more convenient for patients, but adds the pill burden of the ritonavir capsules and the side effects associated with this agent, including gastrointestinal intolerance and lipid abnormalities. Indinavir must be taken on an empty stomach to ensure adequate absorption. Specifically, the dose should be taken one hour before or two hours after a meal. Food, particularly meals that are high in fat, calories, and protein, can reduce the absorption of Indinavir by as much as seventy to eighty percent, leading to subtherapeutic plasma levels and increasing the risk of virological failure and the emergence of drug resistance. Patients who are unable to adhere to the fasting requirement may consume a light, low-fat snack such as dry toast with jam, a cornflake cereal with skim milk, or a small serving of fruit, which does not affect Indinavir absorption. Adequate hydration is a critical component of Indinavir therapy, and patients should be counseled to drink at least one and a half liters, equivalent to approximately six eight-ounce glasses, of water or other non-caffeinated, non-alcoholic fluids per day to prevent the development of nephrolithiasis, or kidney stones, which is a well-recognized adverse effect of the drug. This recommendation for increased fluid intake should be maintained throughout the course of therapy and reinforced at every follow-up visit. If a dose of Indinavir is missed, the patient should take the missed dose as soon as possible, provided that the next scheduled dose is not imminent. If it is nearly time for the next dose, the missed dose should be skipped, and the regular schedule should be resumed. Doses should never be doubled to make up for a missed one, as this can increase the risk of nephrolithiasis and other dose-dependent toxicities. The importance of strict adherence to the dosing schedule should be emphasized, as even brief interruptions in therapy can allow for viral replication and the development of drug-resistant mutants. For patients with mild to moderate hepatic impairment due to cirrhosis, a dose reduction to six hundred milligrams every eight hours is recommended, as the metabolism of Indinavir is reduced, leading to higher plasma drug levels. In patients with severe hepatic impairment, Indinavir should be used with extreme caution, if at all, as the pharmacokinetics in this population have not been well characterized and the risk of toxicity is increased. No dose adjustment is required for renal impairment, as Indinavir is primarily metabolized by the liver, with only a small fraction, less than twenty percent, excreted unchanged in the urine. However, the risk of nephrolithiasis is increased in patients with pre-existing renal disease, and these patients should be monitored particularly closely. Indinavir capsules should be stored at room temperature between fifteen and thirty degrees Celsius and should be kept in their original container with the desiccant canister, as the capsules are sensitive to moisture. The container should be kept tightly closed, and the medication should not be stored in the bathroom or other areas with high humidity. The desiccant canister should not be removed from the bottle, as it protects the capsules from ambient moisture that could degrade the active ingredient. Patients should be advised to check the expiration date on the bottle and to discard any expired medication.
Side effects associated with indinavir therapy
Indinavir is associated with a distinctive spectrum of side effects that reflect both its pharmacological properties as a protease inhibitor and its specific chemical structure. Nephrolithiasis, or the formation of kidney stones, is the most characteristic and clinically significant adverse effect of Indinavir, occurring in approximately four to twelve percent of patients in clinical trials and post-marketing surveillance. Unlike the calcium oxalate or calcium phosphate stones that constitute the majority of kidney stones in the general population, Indinavir-associated stones are composed of the drug itself or its metabolites, which precipitate in the renal tubules and collecting system when their concentration in the urine exceeds their solubility. The risk of stone formation is increased in patients who are inadequately hydrated, as low urine volume leads to higher urinary drug concentrations that favor precipitation. Patients with a history of nephrolithiasis, those living in hot climates where insensible fluid losses are high, and those who engage in strenuous physical activity without compensating with increased fluid intake are at increased risk. The stones typically present with the classic renal colic syndrome, including severe, intermittent flank pain radiating to the groin, hematuria, dysuria, and nausea and vomiting. Management consists of vigorous hydration, analgesia for pain control, and temporary interruption of Indinavir therapy for one to three days during the acute episode. Most stones pass spontaneously without the need for urological intervention. Invariably, Indinavir can be resumed after the episode, with counseling on the critical importance of maintaining high fluid intake and possibly reducing the dose if the stones recur despite adequate hydration. Indirect hyperbilirubinemia is another common and distinctive side effect of Indinavir, occurring in approximately ten to fifteen percent of patients. This manifests as an isolated elevation of unconjugated bilirubin without elevation of liver transaminases or alkaline phosphatase, and without evidence of hepatocellular injury or cholestasis. The hyperbilirubinemia results from the inhibition of the hepatic enzyme uridine diphosphate glucuronosyltransferase 1A1, which is responsible for the conjugation of bilirubin, allowing it to be excreted into bile. Indinavir-induced hyperbilirubinemia is similar in mechanism to Gilbert’s syndrome, a common benign genetic condition characterized by reduced UGT1A1 activity. The elevation in bilirubin is generally mild to moderate and is not associated with clinical jaundice in most patients. It is not a harbinger of liver toxicity, and liver function tests remain normal. However, the bilirubin elevation can be cosmetically concerning if visible jaundice develops, and this effect may lead to discontinuation of the drug in some patients. Gastrointestinal side effects including nausea, vomiting, diarrhea, and abdominal discomfort are common, particularly during the initial weeks of therapy. These symptoms are generally mild to moderate and diminish over time as the gastrointestinal tract adapts to the medication. Taking Indinavir with a light, low-fat snack may help reduce nausea, though the restriction on food intake to ensure adequate absorption of the drug limits the strategies available for managing gastrointestinal symptoms. Persistent diarrhea may require supplementation with oral rehydration solutions and, if severe, may necessitate a change in therapy. Metabolic abnormalities, including hyperlipidemia, hyperglycemia, and lipodystrophy, are recognized as a class effect of protease inhibitors, though the incidence and severity vary among agents. Indinavir has been associated with elevations in total cholesterol, low-density lipoprotein cholesterol, and triglycerides, which may increase the long-term risk of cardiovascular disease. Fasting lipid profiles should be monitored periodically during therapy, and dyslipidemia should be managed according to established cardiovascular risk reduction guidelines, with lipid-lowering medications prescribed when indicated. Insulin resistance and new-onset diabetes mellitus have been reported with protease inhibitor therapy, and some patients may present with hyperglycemia that does not resolve upon discontinuation of the drug. Blood glucose should be monitored regularly, and patients should be counseled about the symptoms of hyperglycemia, including polyuria, polydipsia, weight loss, and fatigue. Lipodystrophy, or fat redistribution syndrome, is a disfiguring and psychologically distressing condition characterized by the loss of subcutaneous fat from the face, limbs, and buttocks, and the accumulation of fat centrally in the abdomen and dorsocervical region, known as a buffalo hump. The pathogenesis of lipodystrophy is complex and appears to involve mitochondrial toxicity and interference with adipocyte differentiation and function. Indinavir and other protease inhibitors have been implicated in this syndrome, though newer agents in the class appear to be associated with a lower incidence. Skin rashes, including maculopapular eruptions and urticaria, have been reported and may require discontinuation of the drug if severe. Dry skin, paronychia, and ingrown toenails are other dermatological effects that have been noted. Headache, fatigue, and dizziness are common but generally mild and transient central nervous system effects. Rare adverse effects include acute hemolytic anemia, spontaneous bleeding in hemophiliacs due to a paradoxical pro-coagulant effect, and hepatic decompensation in patients with underlying chronic hepatitis B or C.
Access Indinavir for your HIV treatment regimen at Happy Family Pharmacy – order online today.
Buy Indinavir (Indinavir Sulphate) Over The Counter at Happy Family Pharmacy
Accessible HIV Treatment – Discreet Worldwide Shipping – Quality Assured
Drug interactions with indinavir
Indinavir is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system, and it participates in a many clinically significant drug interactions that must be carefully managed to avoid toxicity or therapeutic failure. The most important interactions involve other drugs that are metabolized by CYP3A4 and whose levels can be markedly elevated when co-administered with Indinavir. These include certain antiarrhythmic agents such as amiodarone, quinidine, and flecainide, where elevated drug levels can lead to life-threatening cardiac arrhythmias. The concurrent use of these agents with Indinavir is generally contraindicated, and alternative antiarrhythmics should be sought when necessary. Sedative-hypnotics, including midazolam and triazolam, undergo extensive CYP3A4 metabolism, and their co-administration with Indinavir can lead to deep and prolonged sedation, respiratory depression, and coma. These combinations are contraindicated. Ergot alkaloids used for migraine, including ergotamine, dihydroergotamine, and methysergide, are metabolized by CYP3A4, and their accumulation in the presence of Indinavir can cause severe ergotism, characterized by peripheral vasospasm and ischemia, potentially leading to gangrene and the need for amputation of digits or limbs. This combination is absolutely contraindicated. Neuroleptics, including pimozide and possibly other antipsychotics, can accumulate to cardiotoxic levels when co-administered with CYP3A4 inhibitors, increasing the risk of QTc prolongation and torsades de pointes. The concurrent use of Indinavir with simvastatin and lovastatin, statins that are metabolized by CYP3A4, is contraindicated because of the risk of severe myopathy and rhabdomyolysis. Atorvastatin and rosuvastatin are less dependent on CYP3A4 metabolism and may be used with caution at reduced doses. Sildenafil, tadalafil, and vardenafil, phosphodiesterase type 5 inhibitors used for erectile dysfunction, are metabolized by CYP3A4, and their levels are increased by Indinavir. The starting dose of sildenafil should be reduced to twenty-five milligrams, and patients should be warned about the increased risk and duration of side effects including hypotension, visual disturbances, and priapism. The same precautions apply to other PDE5 inhibitors. Rifampin is a potent inducer of CYP3A4 and will dramatically reduce Indinavir plasma levels, leading to subtherapeutic drug concentrations, incomplete viral suppression, and the rapid selection of drug-resistant virus. This combination should be avoided, and if treatment for tuberculosis is required in a patient taking Indinavir, rifabutin, which is a less potent CYP3A4 inducer, should be substituted for rifampin, with appropriate dose adjustments guided by therapeutic drug monitoring. Similarly, St. John’s Wort is a potent inducer of CYP3A4 and P-glycoprotein and can cause significant reductions in protease inhibitor levels, leading to virological failure. Patients must be explicitly cautioned against the use of St. John’s Wort and other herbal supplements without prior consultation with their HIV healthcare provider. Anticonvulsants, including phenytoin, carbamazepine, and phenobarbital, are inducers of CYP3A4 and can reduce Indinavir levels. If anticonvulsant therapy is necessary, agents that do not induce CYP3A4, such as levetiracetam, lamotrigine, or gabapentin, should be considered. The interaction between Indinavir and methadone is bidirectional, as Indinavir can reduce methadone levels through enzyme induction, potentially precipitating opioid withdrawal, while methadone has a minimal effect on Indinavir levels. Patients on methadone maintenance therapy who are starting or changing protease inhibitor therapy should be monitored for signs and symptoms of opioid withdrawal, and their methadone dose should be adjusted accordingly. H2-receptor antagonists such as cimetidine and famotidine, and proton pump inhibitors such as omeprazole and esomeprazole, reduce gastric acidity and can impair the absorption of Indinavir, which is best absorbed in an acidic environment. If acid-reducing therapy is necessary, Indinavir should be administered with a small, acidic beverage such as cola or cranberry juice to enhance absorption, or the Indinavir dose should be administered at least two hours before or after the acid-reducing agent. The combination of Indinavir with other protease inhibitors, particularly when one agent is used to boost the pharmacokinetics of the other, must be approached deliberately. Rifabutin is both a substrate for and an inducer of CYP3A4. When co-administered with Indinavir, rifabutin levels are increased, requiring a reduction in the rifabutin dose to prevent toxicity, while rifabutin’s enzyme-inducing effect necessitates an increase in the Indinavir dose to maintain adequate antiviral levels. This complex interaction requires careful dose adjustment and monitoring. Given the complexity and clinical significance of the drug interactions associated with Indinavir, it is essential that every healthcare provider involved in the care of A HIV-infected patient be aware of the potential interactions with this and other antiretroviral agents, and that a complete and up-to-date medication list, including over-the-counter drugs, herbal supplements, vitamins, and recreational substances, be reviewed before the initiation, modification, or discontinuation of any medication in these patients.